InvestorsHub Logo
Followers 827
Posts 119496
Boards Moderated 15
Alias Born 09/05/2002

Re: DewDiligence post# 5200

Monday, 07/15/2019 6:28:02 PM

Monday, July 15, 2019 6:28:02 PM

Post# of 6723
ABUS/AB-506 CC—Almost all of the Q&A dealt with the fact that four HBV patients (two in each dose cohort) experienced a Grade-4 ALT flare, which caused automatic discontinuation of treatment, according to the trial protocol. These flares occurred after 14 days of monotherapy treatment.

Due to these Grade-4 ALT flares seen in HBV patients, ABUS will conduct a new 28d trial in healthy volunteers to see if there are any Grade-4 ALT flares and, if so, when they occur.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABUS News